EUVIMEDEUVIMED entdecken
Crossref

Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive

Madeline R Hudson iD, Tyler T Tinkham iD, Dan Ilges iD, Cassandra D Votruba iD, Rebecca Corey, Alyssa K McGary iD, Alan Gonzalez iD, McKenna J Beemiller iD, Justin M Potter iD, Ashkan Rastegar iD, Lavanya Kodali iD, Blanca C Lizaola-Mayo iD und 1 weitere

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Madeline R Hudson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Trimethoprim, Sulfamethoxazole Drug Combination, Antibiotic Prophylaxis, Pneumonia, Pneumocystis, Organ Transplantation. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Transplant Center, Mayo Clinic Arizona.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis can prevent Pneumocystis jirovecii pneumonia (PJP) and other opportunistic infections (OI). We sought to assess the frequency, causative factors, and impact of early TMP/SMX discontinuation in abdominal solid organ transplant (SOT). This is a single‐center, retrospective cohort study of abdominal SOT recipients at Mayo Clinic Arizona (MCA) between January 2021 and June 2023. Primary study goals were to determine the rate and reasons behind early TMP/SMX discontinuation and whether TMP/SMX prophylaxis was reinitiated. Secondary outcomes included mean duration of therapy, alternative prophylactic agent utilized, and incidence of TMP/SMX‐preventable OI. A total of 930 abdominal SOT recipients were included (592 kidney, 253 liver, 85 multiorgan transplants). TMP/SMX was discontinued early in 184 (20%) patients: 77 kidney, 84 liver, 23 multiorgan. Predominant reasons for discontinuation were hyperkalemia (39%) and cytopenias (35%). Median duration of TMP/SMX prophylaxis before discontinuation was 54.5 (18.0, 93.2) days. TMP/SMX was not resumed in 62% of cases (36% kidney, 89% liver, 52% multi‐organ). The predominant reason for non‐resumption was alternative prophylaxis with no clear intent to rechallenge TMP/SMX (70%). Alternative prophylaxis included pentamidine (43%), none (30%), dapsone (22%), and atovaquone (5%). Of patients reinitiated, 86% (59/69) successfully remained on TMP/SMX through the prophylaxis period. One TMP‐SMX‐preventable OI (nocardiosis) was observed in the TMP/SMX discontinuation group. TMP/SMX is often discontinued prematurely in SOT recipients without resumption despite resolution of the offending cause. TMP/SMX prophylaxis should be maintained where possible, as alternative therapy may not offer the same broad spectrum of protection against OI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trimethoprim, Sulfamethoxazole Drug CombinationAntibiotic ProphylaxisPneumonia, PneumocystisOrgan TransplantationOpportunistic InfectionsWithholding TreatmentAnti-Bacterial AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedTransplant RecipientsAdultAgedPneumocystis carinii

Stichwörter der Autor:innen

NocardiaPneumocystisprophylaxissolid organtransplantationtrimethoprim/sulfamethoxazole

Substanzen

Trimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Phoenix, Arizona, USA.
  • Transplant Center, Mayo Clinic, Phoenix, Arizona, USA.
  • Department of Quantitative Health Science, Mayo Clinic, Phoenix, Arizona, USA.
  • Division of Nephrology, Mayo Clinic, Phoenix, Arizona, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
  • Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.

ORCID-Profile: Madeline R Hudson, Tyler T Tinkham, Dan Ilges, Cassandra D Votruba, Alyssa K McGary, Alan Gonzalez, McKenna J Beemiller, Justin M Potter, Ashkan Rastegar, Lavanya Kodali, Blanca C Lizaola-Mayo, Holenarasipur R Vikram

Förderung

  • Transplant Center, Mayo Clinic Arizona

Zitieren

APA

Hudson, M. R., Tinkham, T. T., Ilges, D., Votruba, C. D., Corey, R., McGary, A. K., Gonzalez, A., Beemiller, M. J., Potter, J. M., Rastegar, A., Kodali, L., Lizaola-Mayo, B. C., & Vikram, H. R. (2025). Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive. Transplant Infectious Disease. https://doi.org/10.1111/tid.70057

Vancouver

Hudson MR, Tinkham TT, Ilges D, Votruba CD, Corey R, McGary AK, et al. Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive. Transplant Infectious Disease. 2025. doi:10.1111/tid.70057

BibTeX
@article{Hudson2025,
  author = {Hudson, Madeline R and Tinkham, Tyler T and Ilges, Dan and Votruba, Cassandra D and Corey, Rebecca and McGary, Alyssa K and Gonzalez, Alan and Beemiller, McKenna J and Potter, Justin M and Rastegar, Ashkan and Kodali, Lavanya and Lizaola-Mayo, Blanca C and Vikram, Holenarasipur R},
  title = {Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70057}
}
Kostenlos starten →